Lumexa Imaging revenue rises 5% to $272 million in third quarter
Key Facts
Lumexa Imaging reported results on November 10 for the third quarter ended September 30, 2026, posting consolidated revenue of $272.0 million, up 5.0% from the same period last year. Adjusted EPS was $0.26, while GAAP EPS was $0.07. Net income also returned to a profit of $7.2 million, after the company recorded a net loss of $3.5 million in the third quarter of 2025. The results put revenue growth and a return to profitability at the forefront of the company's quarterly performance. The company announced the results in a statement issued Tuesday.
Adjusted EBITDA rose to $62.6 million, compared with $59.1 million a year earlier. Its margin increased to 23.0% from 22.8% in the year-earlier period. The figures show improved adjusted profitability alongside the return to net income, while the gap remains clear between adjusted EPS of $0.26 and GAAP EPS of $0.07. Consolidated revenue rose to $272.0 million from $258.9 million. The results thus combine year-over-year sales growth with gains in earnings and margin.
At the operational level, advanced imaging procedure volume across the system grew 8.1% during the quarter, accounting for 38.2% of total procedures at that level. Chief Executive Caitlin Zulla said advanced modalities reached a record share of total volume. She added: "We are working to open 3 new centers, and we are on track to meet our goal of opening 8–10 new centers this year." The company links its center network expansion to a continued increase in its operating footprint, with openings targeted during 2026. Systemwide figures differ from the company's consolidated measures: consolidated advanced procedure volume grew 7.9%, and its share was 31.8%.
In the second quarter of 2026, revenue was $264.2 million and was in line with analyst expectations, according to Investing.com. Before the third-quarter results were announced, the platform reported that PET procedure volume rose 23.2% year over year in the second quarter, while advanced modalities reached a record 37.4% of total volume. These figures provide context for the growth trajectory in advanced procedures that continued to appear in third-quarter data, when systemwide volume rose 8.1% and its share reached 38.2%. Second-quarter revenue also provides the previous quarterly comparison base of $264.2 million, versus $272.0 million in the third quarter. Third-quarter revenue remained up 5.0% year over year from the same period in 2025.
Lumexa reaffirmed its 2026 revenue outlook of $1.045 billion to $1.097 billion and raised its adjusted EPS range to $0.86–$0.90 from $0.71–$0.77 previously. It also narrowed its adjusted EBITDA outlook to $236–$240 million, with the midpoint remaining at $238 million. The higher adjusted EPS range gives investors a stronger annual indicator, while the annual revenue range is unchanged. The company said the adjusted EPS outlook increase reflects a lower assumed effective tax rate. New openings remain part of its plan for the year: Zulla said the company aims to open 8–10 centers in 2026.
Before the results announcement, LMRI shares closed at $13.97 in the November 9, 2026 session, according to EL7 data. That closing price was from the session before the company announced its third-quarter results on November 10. The statement referenced here did not include a figure for the stock's move after the results were published. The updated annual outlook, particularly the adjusted EPS range of $0.86–$0.90, remains the company's most notable update alongside the quarterly results. The company also kept its annual revenue outlook at $1.045 billion to $1.097 billion.